PharmaTher (PHRRF) has received an Amendment Acknowledgement Letter from the U.S. Food and Drug Administration for its New Drug Application for ...

Ketamine stock PharmaTher Holdings (CSE:PHRM) has received an amendment acknowledgement letter from the U.S. Food and Drug ...

Specialty pharmaceutical company PharmaTher Holdings’ drug application for Ketamine has received a June 4 approval goal date, advancing approval of the drug in the U.S. PharmaTher said it is ...

(RTTNews) - PharmaTher Holdings Ltd. (PHRM), on Wednesday, provided an update on its New Drug Application or NDA for ketamine, announcing plans to resubmit the necessary information to the FDA by ...

PharmaTher Holdings Ltd, a specialty global pharmaceutical company seeking US FDA approval for ketamine, has announced that the company is on track to resubmit information to the US FDA by ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

“I am very pleased with the new FDA approval goal date of June 4, 2025 for our Ketamine drug. We are focused on solving the shortage issue of Ketamine and becoming the leading supplier of Ketamine to ...

TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical ...

(MENAFN- GlobeNewsWire - Nasdaq) The Assigned FDA Approval Goal Date is June 4, 2025 TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the“Company” or“PharmaTher ...